We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.16B
1-Year Est. Return 67.93%
This Fund
S&P 500
This Quarter Est. Return
+20.01%
1 Year Est. Return
+67.93%
3 Year Est. Return
-39.17%
5 Year Est. Return
-45.89%
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$32.7M
Cap. Flow
-$18
Cap. Flow %
-0%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
MCRB icon
Seres Therapeutics
MCRB
+$18

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
1
Moderna
MRNA
$21.5B
$128M 47.6%
4,632,149
– –
SANA icon
2
Sana Biotechnology
SANA
$885M
$68.3M 25.42%
25,001,856
– –
FHTX icon
3
Foghorn Therapeutics
FHTX
$285M
$59.6M 22.19%
12,674,120
– –
MCRB icon
4
Seres Therapeutics
MCRB
$48.1M
$12.8M 4.78%
1,155,850
-2
-0% -$18

Similar funds

AC
AltraVue Capital Bellevue, Washington $1.16B AUM 46.45% 1-Year Est. Return
BI
Bramshill Investments Naples, Florida $1.16B AUM 0.86% 1-Year Est. Return
SCP
Sandhill Capital Partners Buffalo, New York $1.16B AUM 12.37% 1-Year Est. Return
SFG
SNS Financial Group Minneapolis, Minnesota $1.16B AUM 13.88% 1-Year Est. Return
GAB
German American Bancorp Jasper, Indiana $1.16B AUM 25.7% 1-Year Est. Return
AMI
Amica Mutual Insurance Providence, Rhode Island $1.16B AUM 21.34% 1-Year Est. Return
FFP
FourThought Financial Partners Venice, Florida $1.16B AUM 24.95% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Flagship Pioneering's Q2 2025 Portfolio in Review

As of Q2 2025, Flagship Pioneering held 4 positions worth $268M, up 14% from $236M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 4-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's biggest Q2 2025 reduction was Seres Therapeutics, cutting an estimated $18.
  • Flagship Pioneering's ten largest holdings make up 100% of its $268M portfolio in Q2 2025.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q2 2025.
  • Flagship Pioneering's portfolio value rose 14% quarter-over-quarter to $268M.

Based on Flagship Pioneering's 13F filing for Q2 2025, filed 14 Aug 2025.